With Biovac agreement, Pfizer and BioNTech extend their COVID-19 vaccine manufacturing network to Africa ‘Light at the end of the COVID-19 tunnel’ as J&J’s medtech companies rebound to $7B in second-quarter sales YouTube partners with Mass General on health content amid misinformation backlash Catalent makes a $100M splash to add biologics drug substance firepower at Italian plant Sanofi-GSK's COVID-19 vaccine enters EMA rolling review as the companies work on phase 3 trial Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations Biotech earnings arrive under cloud of Delta variant, but Q2 gene editing results still offer reason to celebrate UPDATED Coronavirus tracker: Banner Health unveils $10,000 prize drawings for fully vaccinated employees AbbVie, Roche top data transparency list, but more could be done to build trust in medical system: report Featured Story | By Kevin Dunleavy Lifting patent protections on COVID-19 vaccines could eventually allow poor countries to produce shots. But Pfizer and BioNTech have a more ready solution: The companies have inked manufacturing agreement with Biovac of South Africa, which will allow the companies to supply vaccines to the continent by as soon as next year. read more |
| |
|---|
|
Top Stories By Conor Hale Johnson & Johnson’s medtech companies have rebounded in a big way during this year’s second quarter, outpacing prepandemic earnings in some treatment areas, as the wider market continues to recover from last year’s COVID-19 lockdowns. read more By Heather Landi The first thing many people do when they have a health question is head online. With a deluge of misinformation about COVID-19 and vaccines on the Internet, YouTube is taking steps to surface more credible health information. read more By Fraiser Kansteiner Contract manufacturer Catalent's star has risen sharply over the last year thanks to a series of high-profile COVID-19 vaccine production pacts. Now, it's keeping the momentum going with plans to add biologics firepower at a key factory in the pandemic fight. read more By Kyle LaHucik Sanofi and GlaxoSmithKline passed a small phase 2 COVID-19 vaccine test in mid-May and began enrollment for a global phase 3 later that month, with hopes for a fourth quarter approval. That process picked up steam Tuesday with the European Medicines Agency saying it started a rolling review of the potential vaccine. read more By Fraiser Kansteiner Johnson & Johnson's COVID-19 vaccine delivered $164 million in sales for the second quarter. By year-end, the company expects the shot to gin up $2.5 billion. Meanwhile, the Big Pharma's drug, medical device and consumer health businesses all did gangbusters amid the pandemic recovery, J&J execs said on a Q2 earnings call. read more By Annalee Armstrong The Delta variant driving up COVID-19 infections in the U.S. will certainly cast a pall over earnings, but biotechs saw a boost in the second quarter with some new gene editing results that reinvigorated interest in companies developing the technology. But gene therapy had a moment in the sun, too—one that might have been too bright. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Annalee Armstrong As U.S. officials practically beg the unvaccinated to roll up their sleeves to gain protection from COVID-19, a new report is calling on pharmaceutical companies to be more transparent with their clinical trials and data sharing among peers to build trust in the medical system. A group of Yale bioethicists has found that the largest pharmaceutical companies are better at clinical trial transparency and sharing data amongst their peers and smaller companies could be doing more to catch up. read more |
